25,103 Shares in 10x Genomics $TXG Purchased by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC bought a new position in 10x Genomics (NASDAQ:TXG) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,103 shares of the company’s stock, valued at approximately $291,000.

A number of other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC lifted its position in shares of 10x Genomics by 35.5% in the second quarter. AlphaQuest LLC now owns 39,905 shares of the company’s stock worth $462,000 after buying an additional 10,446 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of 10x Genomics by 12.2% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock worth $69,688,000 after buying an additional 654,597 shares in the last quarter. Ethic Inc. purchased a new stake in shares of 10x Genomics in the second quarter worth about $289,000. ARK Investment Management LLC lifted its position in shares of 10x Genomics by 8.1% in the second quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock worth $160,871,000 after buying an additional 1,046,390 shares in the last quarter. Finally, Cookson Peirce & Co. Inc. purchased a new stake in shares of 10x Genomics in the second quarter worth about $290,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider directly owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 39,149 shares of company stock worth $539,865 in the last ninety days. 9.39% of the stock is owned by insiders.

10x Genomics Price Performance

Shares of TXG stock opened at $13.64 on Friday. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $18.21. The stock’s fifty day moving average price is $12.84 and its 200 day moving average price is $11.53. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -19.49 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same period in the previous year, the business earned ($0.32) EPS. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TXG shares. Piper Sandler started coverage on 10x Genomics in a research note on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective for the company. Zacks Research upgraded 10x Genomics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Barclays reaffirmed an “overweight” rating and set a $15.00 target price (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Canaccord Genuity Group set a $16.00 target price on 10x Genomics in a research report on Monday, August 11th. Finally, Morgan Stanley cut their price target on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $13.65.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.